Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: Post hoc subgroup analyses according to body mass index in a 52-week open-label study

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 11, 2015, Pages 1577-1591

  Inagaki, Nobuya ^a   Goda, Maki ^b   Yokota, Shoko ^b   Maruyama, Nobuko ^b   Iijima, Hiroaki ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Body mass index; Canagliflozin; Japanese; Safety; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLINIDE; GLUCOSE; HEMOGLOBIN A1C; KETONE BODY; SULFONYLUREA; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DIET THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FASTING PLASMA GLUCOSE; FEMALE; FEMALE GENITAL SYSTEM; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; JAPANESE (PEOPLE); KETOACIDOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84936946016     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1055250     Document Type: Article

References (29)

1. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53:6355-60
2. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72
3. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
4. Nelson KM, Reiber G, Boyko EJ; NHANES III. Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002;25:1722-8
5. Sone H, Ito H, Ohashi Y, et al. Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003;361:85
6. Sone H, Yoshimura Y, Ito H, et al. Japan Diabetes Complications Study Group. Energy intake and obesity in Japanese patients with type 2 diabetes. Lancet 2004;363:248-9
7. Horikawa C, Yoshimura Y, Kamada C, et al. Dietary intake in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study. J Diabetes Invest 2014;5:176-87
8. Mannucci E, Alegiani SS, Monami M, et al. DAI (Diabetes and Informatics) Study Group. Indexes of abdominal adiposity in patients with type 2 diabetes. J Endocrinol Invest 2004;27:535-40
9. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-4
10. Tanaka S, Tanaka S, Iimuro S, et al. Body mass index and mortality among Japanese patients with type 2 diabetes: pooled analysis of the Japan diabetes complications study and the Japanese elderly diabetes intervention trial. J Clin Endocrinol Metab 2014;99:E2692-6
11. Kushiyama A, Yoshida Y, Kikuchi T, et al. Twenty-year trends of increasing obesity in young patients with poorly controlled type 2 diabetes at first diagnosis in urban Japan. J Diabetes Invest 2013;4:540-5
12. Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract 2007;61(s153):3-9
13. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity. J Nutr 2001;131:354S-60S
14. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, 12-week study. Diabetes Obes Metab 2013;15:1136-45
15. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebocontrolled, Phase III study. Expert Opin Pharmacother 2014;15:1501-15
16. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Invest 2015;6:210-18
17. Saito Y, Shirai K, Nakamura T, et al. Diabetes complicated by obesity evidence-based practice guideline for the treatment for diabetes in Japan 2013. J Jpn Soc Study Obes 2011;17(Suppl):1-78
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
19. Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015;14:795-800
20. Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 2014;37:634-43
21. Dailey GE, Gao L, Aurand L, et al. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. Diabetes Obes Metab 2013;15:1085-92
22. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54
23. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-6
24. Barnett AH, Cradock S, Fisher M, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9
25. Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26:501-5
26. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014;14:37
27. Cox M, Nelson D. Carbohydrate biosynthesis. Lehninger's Principle of Biochemistry. 3rd edition. Worth; New York: 2000. p. 722-33
28. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:1087-95
29. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50